Benzinga · Aug 24, 2026
Roth Capital Reiterates Buy on Cingulate, Lowers Price Target to $9
Roth Capital analyst Boobalan Pachaiyappan reiterates Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $10 to $9.
CI
NASDAQ · CING
Cingulate Inc.
Healthcare · Biotechnology
$5.17
Down-$0.04 (-0.77%)
Updated Sep 11, 2026, 5:30 AM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 23.43M
- P/E ratio
- -0
- Dividend yield
- 0.00%
- 52-week range
- $3.16 – $11.89
- Volume
- 118.08K
- Avg. volume
- 177.3K
Price performance
CING price history
1M range · 20 trading sessions · Daily adjusted prices
CING closed at $5.17 after 20 trading sessions, up 3.61% for the selected period.
- Last close
- $5.17
- Period change
- +3.61%
- Period low
- $4.99
- Period high
- $5.87
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $5.17 | $5.41 | $5.155 | $5.17 | 118.08K |
| Sep 9, 2026 | $5.24 | $5.40 | $5.16 | $5.21 | 72.53K |
| Sep 8, 2026 | $5.09 | $5.28 | $5.05 | $5.19 | 76.73K |
| Sep 4, 2026 | $5.21 | $5.4979 | $5.02 | $5.10 | 106.98K |
| Sep 3, 2026 | $5.19 | $5.27 | $5.06 | $5.22 | 82.37K |
| Sep 2, 2026 | $5.14 | $5.25 | $5.11 | $5.15 | 83.58K |
| Sep 1, 2026 | $5.16 | $5.215 | $5.03 | $5.11 | 70.59K |
| Aug 31, 2026 | $5.33 | $5.33 | $5.02 | $5.17 | 202.39K |
| Aug 28, 2026 | $5.48 | $5.49 | $5.2559 | $5.325 | 109.12K |
| Aug 27, 2026 | $5.50 | $5.60 | $5.37 | $5.44 | 150.6K |
| Aug 26, 2026 | $5.86 | $5.86 | $5.36 | $5.40 | 158.04K |
| Aug 25, 2026 | $5.71 | $5.94 | $5.65 | $5.87 | 165.69K |
| Aug 24, 2026 | $5.51 | $5.93 | $5.335 | $5.68 | 279.83K |
| Aug 21, 2026 | $5.35 | $5.55 | $5.18 | $5.55 | 234.69K |
| Aug 20, 2026 | $5.21 | $5.38 | $5.0371 | $5.33 | 131.6K |
| Aug 19, 2026 | $5.15 | $5.30 | $5.01 | $5.27 | 163.27K |
| Aug 18, 2026 | $5.17 | $5.28 | $5.10 | $5.20 | 103.59K |
| Aug 17, 2026 | $5.11 | $5.315 | $5.08 | $5.21 | 97.6K |
| Aug 14, 2026 | $4.92 | $5.13 | $4.711 | $5.09 | 207.73K |
| Aug 13, 2026 | $4.96 | $5.08 | $4.80 | $4.99 | 240.36K |
Latest CING news
The latest Smart Investors Daily articles mentioning CING.
Stock researchCompany · Overview
CING research
Overview
Company profile and research snapshot.
Company profile
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $11.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 24, 2026 | Roth Capital | Buy | — |
| Aug 20, 2026 | Ascendiant Capital | Buy | — |
| Jun 8, 2026 | Ascendiant Capital | Buy | — |
| May 26, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 8, 2026 | Ascendiant Capital | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 20, 2026
Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $44
Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $52 to $44.
Benzinga · Aug 13, 2026
Cingulate Q2 EPS $(0.45) Beats $(0.63) Estimate
Cingulate (NASDAQ:CING) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.63) by 28.57 percent. This is a 60.53 percent increase over losses of $(1.14) per share from the
Benzinga · Jul 2, 2026
Cingulate Joins Russell 3000E Index
Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
